Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioXcel Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for BioXcel Therapeutics, Inc.

BTAI

BioXcel Therapeutics, Inc.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop transformative neuroscience and immuno-oncology medicines. Its core business involves repurposing existing drugs using AI-driven platforms to identify new therapeutic indications, focusing on neuropsychiatric disorders and cancer. Key products include IGALMI®, an FDA-approved sublingual film for agitation in schizophrenia and bipolar disorder, and investigational candidates like BXCL501. The company targets patients with unmet medical needs through clinical development and potential partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioXcel Therapeutics, Inc.

1
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports First Quarter 2026 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports $69.9 Million Net Loss and Decreased Product Revenue in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports Decrease in Revenue and Increased Net Loss for Third Quarter 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports Significant Revenue Decline and Increased Net Loss for June 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports $7.254 Million Net Loss and Decreased Product Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports $59.6M Net Loss and Increased Revenue in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BioXcel Therapeutics, Inc. BioXcel Therapeutics Reports Reduced Losses and Operating Expenses, Focuses on Neuroscience and Immuno-Oncology Programs

Via official filing (AI summary) | over 1 year ago | 0 comments